Central Nervous System Diseases clinical trials at UC Irvine
1 research study open to eligible people
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
open to eligible people ages 60-90
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate video scale assessments.
Irvine, California and other locations